DelveInsight’s, “Sialorrhea – Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Sialorrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Sialorrhea: Overview
Sialorrhea, drooling or excessive salivation is a common problem in neurologically impaired children and in adults who have Parkinson's disease or have had a stroke. It is most commonly caused by poor oral and facial muscle control. Sialorrhea can lead to significant physical and psychosocial complications, including perioral chapping, dehydration, infection, foul odor, stigmatization, and increased dependency and level of care, all of which can create an additional burden for these medically complicated patients. Sialorrhea usually is caused by neuromuscular dysfunction, hypersecretion, sensory dysfunction, or anatomic (motor) dysfunction. The most common cause is neuromuscular dysfunction. Anterior sialorrhea is diagnosed by the observation of excessive drooling. Posterior sialorrhea can be suggested by the history of choking and repeated pneumonias. Treatment for Sialorrhea range from conservative (i.e., observation, postural changes, biofeedback) to more aggressive measures such as medication, radiation, and surgical therapy.
"Sialorrhea - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sialorrhea pipeline landscape is provided which includes the disease overview and Sialorrhea treatment guidelines. The assessment part of the report embraces, in depth Sialorrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sialorrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Sialorrhea R&D. The therapies under development are focused on novel approaches to treat/improve Sialorrhea.
This segment of the Sialorrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sialorrhea Emerging Drugs
NT0502: Aytu BioPharma
NT0502 (N-desethyloxybutynin) is an oral, once- or twice-daily potential treatment to reduce chronic sialorrhea in patients with neurological and other conditions associated with drooling and excessive salivation. In December 2020, Aytu BioScience and Neos Therapeutics announced that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction. In March 2022, Aytu BioScience announced close of merger with Neos Therapeutics. . NT0502 is currently in Phase 1 clinical development for treatment of chronic sialorrhea.
Further product details are provided in the report……..
This segment of the report provides insights about the different Sialorrhea drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 3+ key companies which are developing the therapies for Sialorrhea. The companies which have their Sialorrhea drug candidates in the most advanced stage, i.e. Phase II include, Aytu BioPharma.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Sialorrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sialorrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sialorrhea drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Sialorrhea: Overview
Pipeline Therapeutics
Therapeutic Assessment
Sialorrhea – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Sialorrhea Collaboration Deals
Late Stage Products (Phase III)
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
OC oral solution: Orient pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
NT0502: Aytu BioPharma
Drug profiles in the detailed report…..
Preclinical stage products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Sialorrhea Key Companies
Sialorrhea Key Products
Sialorrhea- Unmet Needs
Sialorrhea- Market Drivers and Barriers
Sialorrhea- Future Perspectives and Conclusion
Sialorrhea Analyst Views
Sialorrhea Key Companies
Appendix
List of Table
Table 1: Total Products for Sialorrhea
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Sialorrhea
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Nobelpharma
• Aytu BioPharma
• NeuroHealing Pharmaceuticals
• Orient Pharma
